Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Baxdrostat in Healthy Japanese and Caucasian Subjects
NCT05966324Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of baxdrostat in hypertension (HTN) (4 cohorts), sponsored by AstraZeneca. Primary endpoints: Incidence of treatment emergent adverse events, Area under the curve and 4 more. Started Jul 2022; status: completed.
02
Drugs
baxdrostat
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05966324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05966324.